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The future of anti-cancer therapy is promising as 
immunotherapy strategies have been revolutionary in 
treatment of a number of cancers. However, some organs 
such as the liver are characterised by immunosuppression 
of CD4+ and CD8+ activity, necessitating alternative 
strategies for cancers in such tissues. This occurs at least 
partly through aberrant expression of alpha-fetoprotein 
that in turn dampens immune activation (1). Hepatocellular 
carcinoma (HCC) is the second leading cause of death 
from cancer worldwide (2). Complementary strategies 
to CD4+ and CD8+ T cell-mediated immunotherapies 
that specifically target HCC are needed for the future of 
effective and comprehensive cancer therapy. On the short-
list for a molecular target for such a therapy is CD147/
EMMPRIN.
CD147 is a transmembrane vesicular and cell-surface 
glycoprotein with two N-terminal extracellular-oriented 
immunoglobulin domains. CD147 was discovered as a 
factor produced from tumour cells that induced matrix 
metalloproteinases (MMPs) and collagenase activity from 
fibroblasts (3), thus gaining the moniker extracellular 
matrix metalloproteinase inducer (EMMPRIN) (4). While 
various tissues have detectable expression of CD147, a 
high percentage of malignant cancers overexpress the 
protein, including HCC (5,6). The use of 131I labelled 
CD147 specific humanized antibodies has been approved 
by the Chinese Food and Drug Administration under 
the drug name licartin or metuximab, and is entering 
Chinese clinics (7). Niu et al. were able to show that 
immunologically increasing the concentration of the 
radioisotope at tumor sites results in diminished tumor 
size and extended survival for treated rabbits relative to 
controls (8). Furthermore, individuals with advanced HCC 
who received licartin post-liver transplantation had less 
recurrence of HCC compared to placebo one year post-
transplantation (26.7% vs. 57.1%) (9).
Despite advances in using CD147 as a tumor targeting 
molecule, the biology of CD147 remains complex, with multiple 
regulating factors and pluripotent activities (Figure 1) (4,6). 
The alias EMMPRIN indicates CD147’s role in inducing 
fibroblasts to secrete MMPs, namely MMP-1, MMP-2, 
MMP-3, MMP-9, MT1-MMP, and MT2-MMP (4,10). 
The stimulatory effect of these proteases could play a role 
in activating invasion and metastasis, one of the hallmarks 
of cancer (13). CD147 can homo-oligomerize and bind 
a number of binding partners such as cyclophilin A and 
monocarboxylate transporters (MCTs). Soluble cyclophilin 
A promotes migration and proliferation of multiple 
myeloma cells by binding to CD147, and plays a role in 
chemotaxis of myeloma cells from the blood to the bone 
marrow (14). CD147 complexes with MCTs to symport 
lactic acid and protons out of the cell, acidic products of the 
fermentative glycolysis produced by rapidly proliferating 
tumour cells (11). In the context of tumor growth, 
this function of CD147 allows rapid proliferation and 
metabolism by glycolysis, the “Warburg effect”, without 
generating an acidic intracellular milieu. Over-expression 
of CD147 correlates with higher glucose uptake, lactate 
production, and diminished p53 expression relative to 
CD147 silenced cells (12,15).
Rapidly proliferating tumor tissue requires energy 
consumption yielded by glycolysis and lactic acid 
Editorial
CD147 handles lipid: a new role for anti-cancer target
Daniel J. Felmlee1, Thomas F. Baumert2,3,4
1Hepatology Research Group, Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK; 2Inserm, U1110, Institut 
de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France; 3Université de Strasbourg, Strasbourg, France; 4Institut Hospitalo-
Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Correspondence to: Thomas F. Baumert, MD. Inserm Unit 1110, Hôpitaux Universitaires de Strasbourg, 3 rue Koeberlé, F-67000 Strasbourg, France. 
Email: Thomas.Baumert@unistra.fr; Daniel J. Felmlee, PhD. Plymouth University Peninsula Schools of Medicine & Dentistry, The John Bull 
Building, Research Way, Plymouth PL6 8BU, UK. Email: Daniel.Felmlee@plymouth.ac.uk.
Submitted May 21, 2016. Accepted for publication Jun 02, 2016.
doi: 10.21037/tcr.2016.06.28
View this article at: http://dx.doi.org/10.21037/tcr.2016.06.28
239Translational Cancer Research, Vol 5, No 3 June 2016
© Translational Cancer Research. All rights reserved. Transl Cancer Res 2016;5(3):238-240 tcr.amegroups.com
fermentation, and also needs production of cellular 
components for cell division, including a high demand 
for phospholipid synthesis. Since CD147 appears to act 
as a control switch for cells to enter anaerobic glycolysis, 
could this have knock-on effects into lipid metabolism? Li 
and colleagues utilized 4 public RNA-seq datasets of HCC 
tissues and found a correlation between CD147 expression 
and increased expression of genes involved in fatty acid 
metabolism (7). The authors then used two different HCC 
cell lines to down-regulate or knock out CD147 expression, 
along with restoring CD147 expression in the knocked-out 
line, to observe differences in fatty acid metabolism. CD147 
expressing cells not only had higher levels of phospholipids 
but also had high triglyceride levels; similar to the lipid 
droplet accumulation observed in cancers previously (16). 
CD147 expression correlated with the lipogenesis promoting 
transcription factor SREBP1c, as well as downstream genes 
encoding lipogenic enzymes. Lipogenesis in HCC has 
been associated with the AKT-mTORC1 pathway (17), 
and analysis of these engineered cells showed that CD147 
expression aligned with activation of this pathway. Similar 
lines of evidence showed correlations between diminished 
fatty acid oxidation genes through suppression of 
transcription factor PPARα through MAPK signalling. The 
authors then implanted the CD147 knocked-out HCC cell 
lines, the cells with ectopically restored SREBP1c expression, 
or the cells with silenced PPARα expression into the livers of 
nude mice. Both increased lipogenesis and diminished fatty 
acid oxidation separately could restore oncogenesis despite 
CD147 knockout, indicating that fatty acid metabolism is a 
key instrument in which CD147 is oncogenic.
CD147 is overexpressed in a number of tumor types and 
is a therapeutic target for directed immune-radiotherapy 
against HCC. Investigation of CD147 has revealed a 
number of different functions for the protein yet with 
ambiguous direct effects. Li et al. used genetic techniques 
to show that CD147 exerts tumorigenic activity by both 
upregulating lipogenesis and down-regulating fatty acid 
oxidation, thus meeting the phospholipid requirements 
for cell proliferation. The multiple roles played by CD147 
appear related in that they all encourage rapid proliferation. 
These roles include inducing MMPs to restructure the 
extracellular matrix to make space for new cells, eschewing 
lactate to encourage rapid glycolysis and energy production, 
and now promoting lipogenesis to build membranes of 
daughter cells. The mystery that remains to be clarified is 
how does CD147, a surface transmembrane protein, play 
all of these roles. Since CD147 is a transmembrane protein 
with characteristic N-terminal immunoglobulin domains, 
the effect is likely through signalling but there is a paucity 
of data describing intrinsic signalling motifs in CD147 (4). 
There is much cross-talk between glucose and lipid 
metabolism pathways and it may be difficult to precisely 
define the mechanism involving CD147’s role in these 
processes. Investigations into this hub of so many oncogenic 
effects need to occur in order to improve our understanding 
of tumor development and treatment.
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Figure 1 The multiple functions of CD147/EMMPRIN. CD147 
was identified as a factor that induced matrix metalloproteinases 
(MMPs) to restructure the extracellular matrix (10). It also plays an 
important role in inducing monocarboxylate transporters (MCTs) 
and hetero-dimerizing with them to export damaging fermentative 
glycolysis products, lactate and protons (11). Investigators in 
Xi’an, China have identified that CD147 expression upregulates 
SREBP1c, and represses PPARα and p53 (7,12). The downstream 
effects result in increased lipogenesis, decreased fatty acid 
oxidation, and increased glycolysis. This metabolic profile suits 
rapidly proliferating tumors.
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